NewsBenzingaJP Morgan maintient sa recommandation neutre sur Sarepta Therapeutics et relève son objectif de cours à 22 $ JP Morgan maintient sa recommandation neutre sur Sarepta Therapeutics et relève son objectif de cours à 22 $ Benzinga 2026.11.19 19:08 (GMT+0) Open on Benzinga Other news JP Morgan Maintains Neutral on Eagle Materials, Lowers Price Target to $190 'Meta Bets on $300 Muse Charm to Boost AI Hardware Business'- The Information JP Morgan Maintains Overweight on CRH, Lowers Price Target to $110 Dow Tumbles 900 Points; Walmart Raises Full-Year Guidance JP Morgan Maintains Overweight on Zai Lab, Raises Price Target to $37 'Tesla Shareholders Urged to Vote Against Chair by Proxy Adviser'- Bloomberg